Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3616 + Endocrine Therapy in HR+/HER2- Breast Cancer Adjuvant Therapy
NCT05780567Phase 3Active, not recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing TQB3616 + Endocrine Therapy with Placebo + Endocrine Therapy (2 arms). Primary endpoint: Invasive Disease-Free Survival at 60 months. Started Mar 2023; status: active, not recruiting.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05780567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05780567.